M. Narimatsu et al., THERAPEUTIC USEFULNESS OF WILD-TYPE P53 GENE INTRODUCTION IN A P53-NULL ANAPLASTIC THYROID-CARCINOMA CELL-LINE, The Journal of clinical endocrinology and metabolism, 83(10), 1998, pp. 3668-3672
Anaplastic thyroid carcinomas very often harbor the mutations in the t
umor suppressor gene p53. We have previously shown that wildtype (wt)
p53 gene introduction led to cell growth arrest, but not apoptosis, in
p53-null anaplastic thyroid carcinoma cells. The present studies were
designed to evaluate other therapeutic effects of wt-p53 gene introdu
ction on p53-null thyroid carcinoma cells, as chemo- and radiosensitiz
ation and inhibition of angiogenesis have also been described recently
as additional therapeutic advantages of wt-p53 gene introduction in t
umor cells with p53 mutations. A p53-null anaplastic thyroid carcinoma
cell line, FRO, and a FRO subline stably expressing a temperature-sen
sitive (ts) mutant of p53 (p53Val138): tsFRO, were used. ts-p53 functi
ons as mutant and wt at nonpermissive (37 C) and permissive (32 C) tem
peratures, respectively, tsFRO showed a prolonged cell doubling time c
ompared to parental FRO when cultured at 32 C, but the cell growth rat
e was similar between FRO and tsFRO at 37 C. The cytotoxic and clonoge
nic assays demonstrated that although the sensitivity to three differe
nt anticancer agents (cisplatin, 5-fluorocytosine, and doxorubicin) wa
s unaltered, radiosensitivity was enhanced in tsFRO compared to FRO at
32 C. Unexpectedly, in studies on angiogenesis, expression levels of
vascular endothelial growth factor (an angiogenic factor) messenger ri
bonucleic acid were similar between FRO and tsFRO, and thrombospondin-
1 (an antiangiogenic factor) messenger ribonucleic acid and protein le
vels were about 2.5-fold lower in tsFRO than FRO at 32 C, although any
difference could not be detected in their ability to inhibit in vitro
angiogenesis with the culture medium conditioned by tsFRO and FRO at
32 C. These results suggest that p53-defective thyroid carcinomas may
benefit from the combination of p53 gene therapy and radiotherapy. How
ever, further study will be necessary to clarify the pathological sign
ificance of thrombospondin-1 in angiogenesis and thyroid tumor growth.